ATE245030T1 - Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen - Google Patents
Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesenInfo
- Publication number
- ATE245030T1 ATE245030T1 AT95912577T AT95912577T ATE245030T1 AT E245030 T1 ATE245030 T1 AT E245030T1 AT 95912577 T AT95912577 T AT 95912577T AT 95912577 T AT95912577 T AT 95912577T AT E245030 T1 ATE245030 T1 AT E245030T1
- Authority
- AT
- Austria
- Prior art keywords
- antigen
- heteropolymers
- autoimmune diseases
- human
- passing
- Prior art date
Links
- 229920000140 heteropolymer Polymers 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000006834 complement receptors Human genes 0.000 abstract 2
- 108010047295 complement receptors Proteins 0.000 abstract 2
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20257294A | 1994-02-28 | 1994-02-28 | |
| PCT/US1995/002165 WO1995022977A1 (en) | 1994-02-28 | 1995-02-28 | Antigen-based heteropolymers and method for treating autoimmune diseases using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE245030T1 true ATE245030T1 (de) | 2003-08-15 |
Family
ID=22750436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95912577T ATE245030T1 (de) | 1994-02-28 | 1995-02-28 | Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5879679A (de) |
| EP (1) | EP0743856B1 (de) |
| JP (1) | JPH09509572A (de) |
| AT (1) | ATE245030T1 (de) |
| AU (1) | AU696964B2 (de) |
| CA (1) | CA2183535A1 (de) |
| DE (1) | DE69531290T2 (de) |
| DK (1) | DK0743856T3 (de) |
| ES (1) | ES2207646T3 (de) |
| PT (1) | PT743856E (de) |
| WO (1) | WO1995022977A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE245030T1 (de) * | 1994-02-28 | 2003-08-15 | Univ Virginia | Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen |
| JP2003516526A (ja) | 1999-11-28 | 2003-05-13 | ラ ホヤ ファーマシューティカル カンパニー | 抗体親和性に基づいて狼瘡を処置する方法およびスクリーニング方法ならびにその使用のための組成物 |
| WO2002046208A2 (en) * | 2000-11-01 | 2002-06-13 | Elusys Therapeutics, Inc. | Method of producing biospecific molecules by protein trans-splicing |
| CA2441057A1 (en) * | 2001-03-15 | 2002-09-26 | Elusys Therapeutics, Inc. | Polyclonal populations of bispecific molecules and methods of production and uses thereof |
| WO2003007971A1 (en) * | 2001-07-17 | 2003-01-30 | University Of Virginia Patent Foundation | Improved heteropolymer complexes and methods for their use |
| US20030114405A1 (en) * | 2001-08-13 | 2003-06-19 | Linnik Matthew D. | Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function |
| US7378094B2 (en) * | 2001-08-29 | 2008-05-27 | University Of Virginia Patent Foundation | Therapeutic uses of complement receptor 2 |
| US7105135B2 (en) * | 2001-10-16 | 2006-09-12 | Lockheed Martin Corporation | System and method for large scale detection of hazardous materials in the mail or in other objects |
| JP2006501816A (ja) * | 2002-05-13 | 2006-01-19 | エリューシス セラピューティクス，インコーポレーテッド | 二重特異性分子の精製組成物および生産方法 |
| US20040033232A1 (en) * | 2002-06-13 | 2004-02-19 | Ramberg Elliot R. | Methods and compositions for in vivo clearance of pathogens |
| JP2005538738A (ja) * | 2002-09-16 | 2005-12-22 | エリューシス セラピューティクス，インコーポレーテッド | 抗原結合性抗体フラグメントに架橋された抗ｃｒ１抗体を含む二重特異性分子 |
| US20040208864A1 (en) * | 2002-12-27 | 2004-10-21 | Vibeke Strand | Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
| JP2007525446A (ja) * | 2003-03-28 | 2007-09-06 | エルシス セラピューティクス， インク． | 抗体活性の転換のための方法及び組成物 |
| US20040258683A1 (en) * | 2003-03-30 | 2004-12-23 | Linnik Matthew D. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
| US7405342B2 (en) | 2003-05-09 | 2008-07-29 | University Of Massachusetts | Transgenic mice expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor |
| US9493538B2 (en) * | 2004-05-28 | 2016-11-15 | University Of Massachusetts | Snares for pathogenic or infectious agents and uses related thereto |
| WO2006050291A1 (en) * | 2004-10-29 | 2006-05-11 | Elusys Therapeutics, Inc. | Use of cr1-binding molecules in clearance and induction of immune responses |
| CN101500592A (zh) | 2005-11-07 | 2009-08-05 | 斯克利普斯研究院 | 控制组织因子信号转导特异性的组合物和方法 |
| US8828077B2 (en) * | 2006-03-15 | 2014-09-09 | Medinol Ltd. | Flat process of preparing drug eluting stents |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9518087B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| FR2968304B1 (fr) * | 2010-12-01 | 2014-03-14 | Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic | Nouveaux epaississants cationiques, exempts d'huile et de tensioactifs, procede pour leur preparation et composition en contenant. |
| BR112014020304A8 (pt) * | 2012-02-15 | 2018-01-16 | Ecole Polytechnique Fed Lausanne Epfl | terapêutica para ligação de eritrócitos |
| SG10202010936RA (en) | 2014-02-21 | 2020-12-30 | Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| JP7278270B2 (ja) * | 2017-10-20 | 2023-05-19 | シーエスエル、リミテッド | 方法 |
| WO2019217628A1 (en) | 2018-05-09 | 2019-11-14 | The University Of Chicago | Compositions and methods concerning immune tolerance |
| EP4574842A1 (de) * | 2023-12-22 | 2025-06-25 | Deutsches Rheuma-Forschungszentrum Berlin | Bispezifisches konjugat für antigenspezifische b-zelldepletion durch t-zellen |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992005801A1 (en) * | 1990-10-04 | 1992-04-16 | University Of Virginia Alumni Patents Foundation | Primate erythrocyte bound monoclonal antibody heteropolymers |
| ATE245030T1 (de) * | 1994-02-28 | 2003-08-15 | Univ Virginia | Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen |
-
1995
- 1995-02-28 AT AT95912577T patent/ATE245030T1/de not_active IP Right Cessation
- 1995-02-28 JP JP7522419A patent/JPH09509572A/ja active Pending
- 1995-02-28 AU AU19677/95A patent/AU696964B2/en not_active Ceased
- 1995-02-28 DE DE69531290T patent/DE69531290T2/de not_active Expired - Fee Related
- 1995-02-28 EP EP95912577A patent/EP0743856B1/de not_active Expired - Lifetime
- 1995-02-28 PT PT95912577T patent/PT743856E/pt unknown
- 1995-02-28 ES ES95912577T patent/ES2207646T3/es not_active Expired - Lifetime
- 1995-02-28 DK DK95912577T patent/DK0743856T3/da active
- 1995-02-28 CA CA002183535A patent/CA2183535A1/en not_active Abandoned
- 1995-02-28 WO PCT/US1995/002165 patent/WO1995022977A1/en not_active Ceased
- 1995-06-05 US US08/460,861 patent/US5879679A/en not_active Expired - Fee Related
-
2001
- 2001-10-26 US US10/016,763 patent/US20020103343A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2183535A1 (en) | 1995-08-31 |
| EP0743856B1 (de) | 2003-07-16 |
| DE69531290T2 (de) | 2004-05-13 |
| AU1967795A (en) | 1995-09-11 |
| EP0743856A4 (de) | 2000-04-12 |
| DE69531290D1 (de) | 2003-08-21 |
| DK0743856T3 (da) | 2003-11-10 |
| AU696964B2 (en) | 1998-09-24 |
| US5879679A (en) | 1999-03-09 |
| WO1995022977A1 (en) | 1995-08-31 |
| EP0743856A1 (de) | 1996-11-27 |
| JPH09509572A (ja) | 1997-09-30 |
| ES2207646T3 (es) | 2004-06-01 |
| US20020103343A1 (en) | 2002-08-01 |
| PT743856E (pt) | 2003-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE245030T1 (de) | Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen | |
| DE69531679D1 (de) | Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper | |
| ATE347565T1 (de) | Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien | |
| ES2084338T3 (es) | Anticuerpos recombinantes especificos para el tnf alfa. | |
| ATE403680T1 (de) | Herstellung tetravalenter antikörper | |
| NO963168L (no) | Immunstimulatoriske monoklonale antistoffer | |
| UA111707C2 (uk) | Застосування виділеного анти-tnf-альфа антитіла людини | |
| TR200002731T2 (tr) | Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar | |
| ZA946767B (en) | Monocional antibodies having property of causing apoptosis. | |
| ATE132197T1 (de) | Monoklonale antikörper | |
| NO883306D0 (no) | Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev. | |
| DE69840913D1 (de) | Divalent anti-t-zellen immuntoxinen und deren verwendung | |
| ATE205532T1 (de) | Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper | |
| NO973875D0 (no) | Fremgangsmåte for simulering av en immunrespons | |
| PT954333E (pt) | Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas | |
| ATE484294T1 (de) | Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen | |
| DE69615843D1 (de) | Il-8 antagonisten zur behandlung von asthma | |
| ATE251886T1 (de) | Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit | |
| SE8800886L (sv) | Immunglobulinkojugat | |
| ATE100331T1 (de) | Verfahren zur behandlung von septischem schock. | |
| KR910006478A (ko) | 인체 트립타제 유사 단백질 | |
| ATE173503T1 (de) | Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma | |
| EP0959899A4 (de) | LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0743856 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |